GSA Capital Partners’s Bioverativ Inc. Common Stock BIVV Stock Holding History

GSA Capital Partners’s Portfolio BIVV Stock Details BIVV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-64,314	Closed	-$3.47M	–	1984
2017 Q4	$3.47M	Buy	64,314 +27,565	+75%	+$1.51M	0.21%	57
2017 Q3	$2.1M	Buy	36,749 +20,896	+132%	+$1.22M	0.14%	138
2017 Q2	$954K	Buy	15,853 +4,857	+44%	+$277K	0.06%	582
2017 Q1	$599K	Buy	+10,996	New	+$542K	0.03%	983

Other funds holding BIVV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ACS

Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

GSA Capital Partners's BIVV Position: Q1 2018 in Review

GSA Capital Partners sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 64,314 shares — an estimated $3.47M sold.

GSA Capital Partners first reported a position in BIVV in Q1 2017 and held it in 4 quarters. The position peaked at $3.47M in Q4 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

GSA Capital Partners reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
GSA Capital Partners sold 64,314 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $3.47M.
GSA Capital Partners first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 4 quarters.
GSA Capital Partners's Bioverativ Inc. Common Stock position peaked at $3.47M in Q4 2017.
2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on GSA Capital Partners's 13F filing for Q1 2018, filed 11 May 2018.